About this trial
Patients with liver cirrhosis often have impaired or at-risk kidney function due to the close link between liver and kidney (hepatorenal syndrome). Laparoscopic splenectomy is commonly used to treat splenomegaly and hypersplenism in these patients, but its impact on kidney function over 2 years is unclear. This study will follow patients undergoing laparoscopic splenectomy to measure changes in kidney function before and after surgery, identify risk factors for kidney damage and whether laparoscopic splenectomy can improve kidney function in the long term, and help improve care to protect kidney function in cirrhotic patients .
Eligibility criteria
Qualifiers
Confirmed diagnosis of liver cirrhosis (clinical, laboratory, imaging)
Splenomegaly and hypersplenism
No history of portal hypertension bleeding (esophageal and gastric variceal bleeding )
Age 18-80 years, male or female
Disqualifiers
Child-Pugh Class C liver cirrhosis
Primary renal diseases (glomerulonephritis, polycystic kidney disease, chronic pyelonephritis, etc.)
Previous abdominal surgery precluding safe laparoscopic splenectomy
Severe cardiac, pulmonary, cerebrovascular dysfunction; malignant tumors; primary hematological disorders
Trial design
Treatments tested in this trial
- Not listed